Upadacitinib (Rinvoq®) is a once-daily oral JAK1 inhibitor tablet for treating moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis (≥12 years), ulcerative colitis, and Crohn's disease in patients with inadequate response to prior therapies like TNF blockers.
Strengths: Extended-release 15 mg, 30 mg, 45 mg tablets.
Dosing: Once daily, with or without food.
Class: Selective Janus kinase (JAK) inhibitor; targeted synthetic DMARD.
Prescription-only; ideal for convenient at-home autoimmune management with specialist oversight.
USD $395.00
IndiaUpadacitinib (Rinvoq®) is a prescription once-daily oral tablet, a selective JAK1 inhibitor used for moderate-to-severe active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, and Crohn's disease in adults and certain pediatric patients (≥12 years for atopic dermatitis) with inadequate response to prior therapies.
Active ingredient: Upadacitinib (as hemihydrate).
Strengths: Extended-release film-coated tablets: 15 mg, 30 mg, 45 mg.
Class: Janus kinase (JAK) inhibitor; targeted synthetic disease-modifying antirheumatic drug (tsDMARD).
Mechanism: Preferentially inhibits JAK1 enzyme to block inflammatory signaling pathways (JAK-STAT), reducing immune overactivity in autoimmune conditions.
Rheumatoid arthritis (RA): Moderate-to-severe active RA in adults; monotherapy or with methotrexate/csDMARDs after inadequate response/intolerance to DMARDs.
Psoriatic arthritis (PsA): Moderate-to-severe active PsA in adults.
Axial spondyloarthritis: Active non-radiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS) with inflammation (elevated CRP/MRI).
Atopic dermatitis: Moderate-to-severe in adults/pediatrics ≥12 years unresponsive to topical therapies.
Inflammatory bowel disease: Moderately-to-severely active ulcerative colitis (UC) or Crohn's disease (CD) after failure/intolerance to conventional/biologic therapy.
Always confirm with current local Product Information (PI) as indications vary by region.
RA, PsA, AS, nr-axSpA, atopic dermatitis: 15 mg once daily (30 mg for inadequate response; use lowest effective dose).
UC/CD induction: 45 mg once daily (8 weeks); maintenance: 15 mg or 30 mg once daily.
Take with/without food; swallow whole (do not crush/split). No dose adjustment for mild-moderate hepatic/renal impairment; reduce in severe cases or elderly/high-risk patients.
Specialist initiation/monitoring required; regular blood tests for infections, lipids, liver enzymes, blood counts.
Upper respiratory infections, nausea, headache, acne, elevated cholesterol/liver enzymes, anemia, fever, weight gain, herpes zoster/shingles.
Serious risks: Serious infections (TB, bacterial/fungal/viral), MACE (heart attack/stroke), malignancy, VTE (blood clots), GI perforation.
Screen for infections/TB before starting; avoid live vaccines.
Increased risk in smokers, >65 years, CV risk factors; monitor lipids/blood pressure.
Not for use in active serious infections, severe hepatic impairment, pregnancy (embryo-fetal toxicity), or breastfeeding.
Contraindicated with strong immunosuppressants (e.g., other JAKi, biologics).
Convenient at-home oral therapy (no injections/infusions).
Rapid onset: Symptom improvement in 1-4 weeks across indications.
Flexible monotherapy/combination use post-TNF failure.
Store below 25°C in original packaging.
Keep out of reach of children.
Genuine Rinvoq® tablets with prescription. Upload valid prescription for secure, discreet Australia-wide delivery. Perfect for long-term autoimmune management with refill reminders.
